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Keywords: vitamin D, functional genomics, clinical trial, quantitative trait locus 
Short title: Functional genomics analysis of the BEST-D trial 
Key result: Supplementation with high-dose vitamin D in older people for 12 months in 
a randomized, placebo-controlled trial had no significant effect on gene expression or on 
plasma concentrations of selected cytokines. 
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Abstract 
Background 
Vitamin D deficiency has been associated with multiple diseases, but the causal relevance 
and underlying processes are not fully understood. Elucidating the mechanisms of action 
of drug treatments in humans is challenging, but application of functional genomic 
approaches in randomized trials may afford an opportunity to systematically assess 
molecular responses. 
Methods 
In the Biochemical Efficacy and Safety Trial of Vitamin D (BEST-D), a double-blind, 
placebo-controlled, dose-finding, randomized clinical trial, 305 community-dwelling 
individuals aged over 65 years were randomly allocated to treatment with vitamin D3 
4000 IU, 2000 IU or placebo daily for 12 months. Genome-wide genotypes at baseline, 
and transcriptome and plasma levels of cytokines (IFN-γ, IL-10, IL-8, IL-6 and TNF-α) 
at baseline and after 12 months, were measured. The trial had >90% power to detect 1.2-
fold changes in gene expression. 
Findings 
Allocation to vitamin D for 12-months was associated with 2-fold higher plasma levels of 
25-hydroxy-vitamin D (25[OH]D, 4000 IU regimen), but had no significant effect on 
whole-blood gene expression (FDR <5%) or on plasma levels of cytokines compared 
with placebo. In pre-specified analysis, rs7041 (intron variant, GC) had a significant 
effect on circulating levels of 25(OH)D in the low dose, but not on the placebo or high 
dose vitamin D regimen. A gene expression quantitative trait locus analysis (eQTL) 
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demonstrated evidence of 31,568 cis-eQTLs (unique SNP-probe pairs) among individuals 
at baseline and 34,254 after supplementation for 12 months (any dose). No significant 
associations involving vitamin D supplementation response eQTLs were found. 
Interpretation 
We performed a comprehensive functional genomics and molecular analysis of vitamin D 
supplementation in a randomized, placebo-controlled trial. Although this study was 
limited to mostly Caucasian individuals aged over 65 years, the results differ from many 
previous studies and do not support a strong effect of vitamin D on long-term 
transcriptomic changes in blood or on plasma cytokine levels. The trial demonstrates the 
feasibility of applying functional genomic and genetic approaches in randomized trials to 
assess molecular and individual level responses. 
 
Trial registration: SRCTN registry (Number 07034656) and the European Clinical Trials 
Database (EudraCT Number 2011-005763-24). 
 
Funding: Medical Research Council, British Heart Foundation, Wellcome Trust, 
European Research Council and Clinical Trial Service Unit, Nuffield Department of 
Population Health, University of Oxford, Oxford, United Kingdom 
 
Copyright: Open access article under the terms of CC BY.  
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Research in context 
Many studies have reported associations of vitamin D deficiency with different diseases, 
but little is known about the causal relevance of such associations. Genomics 
technologies can provide important tools for discovery and validation of disease and drug 
mechanisms in clinical trials, but have not been widely used. Vitamin D is known to have 
genome-wide effects, but results have mainly come from laboratory models or small 
studies in humans. Results of previous studies differ, possibly reflecting the complexity 
of synthesis and metabolism of vitamin D. In the present study, we used a randomized 
placebo-controlled trial, but did not observe any significant differences in expression in 
genes (genome-wide) or on plasma concentrations of selected cytokines in community-
dwelling older individuals. Vitamin D is essential for human physiology and undoubtedly 
has multiple effects. Such effects are likely to vary between cells, tissues, individuals, 
populations and environmental circumstances. The mechanisms which regulate vitamin D 
are complex and likely to be robust to such differences. The present study shows that 
integrating high throughput molecular measurements is feasible in a community-based 
clinical trial and the results will inform future research investigating the mechanisms of 
action of vitamin D. 
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Introduction 
Randomized controlled trials afford reliable approaches to understand the causal 
relevance of drug treatments and can also help our understanding of disease mechanisms 
by relating changes in biomarkers with incidence of disease or with surrogate markers of 
disease. Advances in molecular methods now permit use of high- throughput functional 
genomics strategies in clinical trials. Application of such approaches has been under-
utilized to date, with previous studies focusing on comparisons of transcriptomes to 
understand mechanisms and identify novel biomarkers (Beck et al., 2014). Animal and 
experimental models of disease pathogenesis have limited ability for translation into 
humans, particularly in the context of complex diseases (Seok et al., 2013, Takao and 
Miyakawa, 2015), while incomplete knowledge of mechanisms contributes to 
inconclusive findings in randomized trials and the current high failure rate in late stage 
drug development. Hence, there is an urgent need to demonstrate the value of combining 
functional genomic approaches, including genome-wide genotyping and gene expression 
profiling, together with measurements of biochemical and clinical markers in clinical 
trials to enhance our understanding of the pathophysiological processes and mechanisms 
of action of novel drug treatments. Such approaches may also allow high-throughput 
assessment of cellular and molecular responses at group and individual levels that can 
also be integrated with effects on clinical outcomes data. Hence, integrated analysis may 
yield clinically relevant insights about treatment that could guide the design of large 
outcome trials. 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
This study applied functional genomics methods to investigate the molecular response to 
vitamin D supplementation. In addition to the established role of vitamin D in calcium 
metabolism and bone disease, accumulating evidence suggests a possible role of vitamin 
D in immune function and inflammatory diseases (Bouillon et al., 2008). Previous studies 
have investigated the associations of vitamin D with gene expression (Carlberg et al., 
2013, Hossein-nezhad et al., 2013, Ramagopalan et al., 2010), but these have typically 
been cross-sectional, in experimental models, involved relatively small sample sizes or 
lacked placebo controls. Moreover, no previous studies have assessed the impact of 
genetic variation on responses to vitamin D supplementation.  
 
The aim of the work described here was to examine the molecular responses to vitamin D 
supplementation in a randomized, placebo-controlled trial. To achieve this, we 
investigated changes in response to treatment after 12 months in whole blood 
transcriptomes and plasma levels of cytokines, in addition to genetic determinants of 
individual responses on circulating 25-hydroxy vitamin D (25[OH]D) and genome-wide 
gene expression, by comparing a total of 305 individuals allocated to daily treatment with 
vitamin D at either 4000 IU, 2000 IU or placebo in the BEST-D trial (Hin et al., 2016). 
 
Methods 
Details of the design, baseline characteristics and data analysis plan and results of the 
BEST-D trial have been reported previously (Clarke et al., 2015, Hin et al., 2016). 
Briefly, the primary objectives of BEST-D were to compare the effects on plasma levels 
of 25(OH)D and to determine the proportion of participants with plasma 25(OH)D levels 
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>90 nmol/L after one year of supplementation with 4000 IU or 2000 IU of vitamin D3 
versus placebo. BEST-D was designed as an intention-to-treat, double-blind, placebo-
controlled, dose-finding, randomized clinical trial. Written informed consent was 
provided by all participants. BEST-D was approved by the National Research Ethics 
Service (NRES) Committee South Central–Oxford B, the Thames Valley Primary Care 
Research Partnership, a Clinical Trial Authorization from MHRA, and is included on the 
National Institute for Health Research (NIHR) Trial portfolio. 
 
Eligible participants were ≥65 years of age, living in the community and ambulatory. 
Participants were randomized in a ratio of 1:1:1 to each group using a minimization 
algorithm balanced for age group (65–69, 70–74, 75 years), gender, body mass index 
(BMI), smoking history, ethnicity and history of fracture. Of 1122 individuals who were 
invited to participate, 313 (33%) agreed to a receive a visit from a study nurse for 
randomisation and 305 (32%) were successfully randomized between 24 September 2012 
and 14 March 2013. All data and results were handled according to the trial and 
institutional guidelines in secure servers within the University of Oxford. All 
comparisons were conducted by intention-to-treat analyses using a pre-specified plan for 
the molecular data analysis (Supplementary Information). 
 
Procedures 
Briefly, a research nurse visited participants at their homes to obtain medical history, 
samples and measurements. PAXgene Blood RNA tubes (Qiagen) were used to ensure 
RNA stability without needing immediate processing. Biological samples were 
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transported at 2-4C and then stored at -80C. RNA and DNA samples were processed at 
the end of the study as detailed below. Plasma 25(OH)D levels were measured using an 
Access 2 immunoassay analyzer (Beckman Coulter Ltd., High Wycombe, England) 
complying with the quality assurance DEQAS scheme. Further details have been 
described previously (Hin et al., 2016). Plasma cytokines were measured using a 
MesoScale Discovery multi-spot assay system. The V-Plex pro- inflammatory panel 1 kit 
was used, with detection antibodies for interferon-gamma (IFN-γ), interleukin 6 (IL-6), 
interleukin 8 (IL-8), interleukin 10 (IL-10) and tumor necrosis factor alpha (TNF-α). In 
brief, assays were sandwich electrochemiluminescence (ECL) immunoassays. Between-
run precision over the experiment for IFN-γ was 11.39% at 91.78 pg/mL and 10.73% at 
10.73 pg/mL; for IL-6 11.15% at 49.20 pg/mL and 13.02% at 8.85 pg/mL; for IL-8 
9.38% at 32.67 pg/mL and 12.76% at 6.75 pg/mL; for IL-10 13.60% at 22.01 pg/mL and 
13.82% at 4.49 pg/mL; and for TNF-α 12.29% at 11.15 pg/mL and 14.36% at 3.19 
pg/mL. 
 
DNA extraction and genotyping 
Genomic DNA was extracted from the buffy coat layer using DNeasy Blood and Tissue 
Kit (Qiagen), and quantified by NanoDrop (Thermo Fisher Scientific; Waltham, MA) and 
Agilent 2100 Bioanalyzer (Agilent Technologies). 299 samples (of 305 possible) were 
available for DNA isolation and were processed over a single batch. Genotyping was 
performed using the Illumina Infinium HumanOmniExpress-24v1-0 (Illumina) beadchips 
following the Infinium HTS protocol (Illumina) at the Oxford Genomics Centre 
(WTCHG). Sample concentration was measured using PicoGreen (Thermo Fisher 
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Scientific) and normalized. In total, 716,503 single nucleotide polymorphisms (SNPs) 
were genotyped. The genotype call rate cut-off was <98%. The overall call rate was 
99.75% with one sample removed at this stage (genotype call rate 96.8%). 
 
RNA extraction, cDNA conversion and microarray measurements 
Total RNA was isolated from whole blood samples using PAXgene Blood RNA Kit 
(Qiagen) with recovery of RNA populations of <200 nucleotides and globin messenger 
RNA clearance using the GLOBINclear Kit (Ambion). Quantification of RNA and 
quality measures were assessed using Agilent 2100 Bioanalyzer (Agilent Technologies) 
and Nanodrop (Thermo Fisher Scientific). Complementary DNA synthesis, labelling and 
microarray hybridization were performed at the Oxford Genomics Centre using Illumina 
Human-HT-12v4 Expression BeadChip (Illumina). In total, 574 samples were available 
for further processing after microarray measurements (of 610 possible from the 305 
participants who completed the study). Thirty samples were not available at end of study, 
four samples failed RNA quality metrics before array hybridization and two during array 
processing. Three additional samples were identified as of low quality due to low 
amounts of complementary RNA upon further inspection. Arrays were run in batches of 
96 randomized samples. 
 
Statistical analysis 
A priori power for detecting gene expression differences 
Statistical power calculations for gene expression analysis for in vivo studies are not well 
documented. We estimated statistical power using available data from vitamin D treated 
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human cell line experiments (Ramagopalan et al., 2010, Wang et al., 2005). We estimated 
that vitamin D3 supplementation may alter gene expression by 1.5 to 3-fold differences. 
Sample size was prioritized for the main trial outcomes (circulating levels of 25[OH]D). 
With a fixed sample size of 100 per group for the BEST-D trial, taking a two-sided alpha 
of 0.05 for a two-sample t-test, beta of 10%, standard deviation of 0.7, and equal size 
group we estimated we would be able to detect effect size differences in mean gene 
expression values of 1.25-fold change per gene. For paired tests, 1.17-fold changes would 
be detectable at the same beta. These estimates assume single gene tests with calculations 
performed using the base package in R and pwr (v1.1-3). Calculations using the R 
package sizepower (v1.48.0), which is specific for microarray experiments, for matched 
samples with the following assumptions: mean number of false positives = 1, genes not 
expected to be differentially expressed = 10,000, mean difference in log-expression 
between comparison groups = 1.20, standard deviation = 0.7, and sample size = 100, 
indicated we had complete power to detect fold changes of 1.2. 
 
Genome-wide SNP processing and statistical analysis 
Quality control was carried out using standard approaches (Anderson et al., 2010, Ritchie 
et al., 2015) and included assessment of gender miss- identification; subject relatedness, 
duplication and divergent ancestry; individuals with elevated missing data rates or 
outlying heterozygosity rate; identification of markers (SNPs) with excessive missing 
data rates; identification of differing genotype call rates between group s; SNP quality 
(filtering of monomorphic SNPs, SNPs with missing values or nonsense values; low call 
rate; violation of Hardy-Weinberg equilibrium; duplication; and minimum allele 
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frequency). We removed low quality markers followed by individuals. We excluded non-
autosomal variants. We used the following criteria for filtering: call rates >98%; minor 
allele frequency (MAF) >10%; Hardy-Weinberg equilibrium threshold of 1x10-6. This 
resulted in 19 SNPs with a significantly different (p-value <0.01) missing data rate 
between cases and controls (treated vs placebo) being excluded; 4,893 variants due to 
missing genotype data; 20 variants due to Hardy-Weinberg equilibrium and 193,723 with 
MAF <10%. In total, 497,136 variants passed QC filters. Of 299 genotyped ind ividuals, 
eleven were excluded after QC: one individual was excluded due to low genotype call 
rate (<98%); two due to gender misidentification; two due to relatedness (identity-by-
descent value >0.1875); three due to ancestry other than Caucasian, and three due to a 
high genotype failure rate (0.03) and/or a heterozygosity rate ±3 SD from the mean 
(Supplementary Figure 1). 
 
Linear regression association tests were conducted using frequentist methods with 
PLINK version 1.90 (Purcell et al., 2007). We corrected for baseline vitamin D 
circulating levels, vitamin D intake (assessed at baseline), season (based on date of trial 
recruitment), gender, age, baseline BMI, medical history (incident fracture, incident 
respiratory infection, diabetes, heart disease, chronic obstructive pulmonary disease, 
asthma) and current smoking status. To explore genetic determinants of 25(OH)D levels 
we only considered SNPs previously identified by GWAS (Wang et al., 2010) and which 
were included in the genotyping array (rs12794714 [CYP2R1], rs2282679 [GC], rs7041 
[GC] and rs7944926 [DHCR7/NADSYN1]). We utilized an adaptive Monte Carlo 
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permutation as implemented by PLINK to derive empirically determined significance 
values.  
 
Quality control, normalization of microarray data and differential gene expression 
analysis 
Quality assessment of gene expression data included visual analysis of un-normalized 
data; analysis of built- in control probes; sample outlier detection and estimation of the 
proportion of probes expressed across samples (Shi et al., 2010a) (Supplementary Figure 
2). Outlier detection was carried out using arrayQualityMetrics v3.24.0 (Kauffmann et 
al., 2009). We removed samples that failed three criteria based on the package’s internal 
scores of individual array quality, homogeneity between arrays and between array 
comparisons. We found that 11 samples were classed as outliers by all three methods. 
Outlier thresholds (sum of the distances to all other arrays, Kolmogorov-Smirnov statistic 
Ka and Hoeffding's statistic Da) were calculated by the package based on the array signal 
intensity values. 
 
We excluded probes not expressed in at least three arrays with detection p-values <0.05. 
Pre-processing and probe filtering included background correction as described in (Shi et 
al., 2010b) using built- in negative controls and VSN normalization. A second procedure 
based on quantile normalization (limma neqc function) was used to test the main results 
of the differential expression analysis. We used the package illuminaHumanv4.db v1.26.0 
as well as the manifest file for Illumina Human-HT-12v4 to annotate gene expression 
probes. We excluded probes from further analysis if probe sequences mapped to more 
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than one genomic location; annealed at regions with SNPs present or mapped to non-
autosomal locations (illuminaHumanv4.db v1.26.0). When mapping cytokines to their 
corresponding mRNA transcripts we found that only IL-10 (ILMN_1674167) did not 
overlap known SNPs. Our final results filtered probes overlapping SNPs (Supplementary 
Table 1), but exclusion of these did not materially alter results. For comparison purposes, 
we present all cytokine transcripts (Figure 3). Principal components analysis was 
performed with R’s prcomp function with scaling and centering.  
  
We performed differential expression comparisons using limma v3.24.15 with linear 
models fit with empirical Bayes analysis (Smyth, 2004). The primary comparison was a 
difference in difference estimator (per gene expression probe). We tested for linear or 
quadratic effects of vitamin D on expression and on the absolute change in expression. 
Additionally, we performed a linear mixed model analysis with the R package lmerTest 
(Bates et al., 2015), using person-specific random effects to account for between-person 
expression heterogeneity and fixed effects for time and time interacted with 25(OH)D 
levels. To account for unknown confounders, we analyzed gene expression differences 
within time-points after correcting for the first 10 surrogate variables using the R 
packages SVA (Leek et al., 2012) and SmartSVA (Chen et al., 2017). We present the 
difference in difference comparisons but did not find significant changes using other 
statistical approaches for the main analysis. 
 
Expression quantitative trait loci (eQTL) analysis 
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We used an additive linear model as implemented in the R package MatrixEQTL v2.1.1 
(Shabalin, 2012) with inclusion of principal components (PC) from gene expression 
samples as covariates. We determined the number of PCs to correct for by running eQTL 
analyses with increasing numbers of PCs until the number of eQTL associations was 
maximized (Fairfax et al., 2014). Statistics and plots were carried out at the probe level. 
We used dbSNP human build 146, probe genomic locations as provided by Illumina, and 
p-value thresholds at <1e-8 for trans and <1e-5 for cis. We used MatrixEQTL’s 
calculation of the false discovery rate (FDR) based on the Benjamini-Hochberg 
procedure. Vitamin D response eQTLs were defined using fold change values without a 
cut-off threshold as input (instead of gene expression values) for association with SNPs 
(FDR <5%) after correcting for PCs per group. The maximum number of PCs to correct 
for was based on independent eQTL analyses of baseline and 12-months samples from 
gene expression values. We used R core packages, biglm (v. 0.9-1) and gvlma (v. 1.0.0.2) 
to regress PCs from gene expression values. We did not correct for population 
stratification as genomic inflation was low (1.01, based on median chi square) and 
unlikely to reflect population stratification (Yang et al., 2011, Bulik-Sullivan et al., 
2015). Similar to the gene expression analysis, we tested for errors in the eQTL pipeline. 
Here we tested our results directly as comparable experiments have been done previously 
in whole blood samples (Westra et al., 2013). Despite differences in sample size, 
genotyping platforms and number of SNPs tested we chose a conservative genomic 
interval overlap test. We used the tool GAT (Heger et al., 2013) with the mappable 
genome as background and genomic intervals defined as plus and minus 1000 nucleotides 
for each SNP and ran the analysis of overlap between our results and (Westra et al., 2013) 
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with 1000 permutations to obtain empirical p-values. Linkage disequilibrium (LD) 
clumping was performed using PLINK version 1.90 (Purcell et al., 2007) based on 
HapMap 3 (release 2) CEU population for eQTL SNPs under FDR 5% with an r2 
threshold of 0.1, distance threshold of 10 kb and p-value of 0.0001. 
 
Statistical analysis of circulating cytokines 
We imputed missing data using multiple imputation methods with 50 datasets, a 
maximum iteration of 50 and predictive mean matching (R packages mice v2.30 and 
miceadds v2.4-12) (van Buuren, 2011). No variable had more than 5% missing values. 
We performed analysis of covariance on each of the log natural transformed values of 
plasma levels of IFN-γ, IL-10, IL-8, IL-6 and TNF-α, accounting for the same 
confounders as in the genotype-25(OH)D analysis and including baseline values for 
every case. Linear regression summary tables presented were processed with the R 
package stargazer v2.3.1. 
 
General software and plotting 
R packages were run with R 3.2.4 (R Core Team, 2016). Custom scripts, sqlite3 (v. 
3.13.0) and data.table (v. 1.9.6) were used for data processing. Figures were generated 
using package specific functions (limma and MatrixEQTL) or with ggplot2 (v. 2.1.0) and 
R’s base plotting. Supplementary Figure 1 was plotted using code from (Anderson et al., 
2010). 
 
Results 
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Effects of vitamin D supplementation on gene expression 
Following sample processing and quality control, genome-wide gene expression data on 
16,760 probes (12,910 genes) were available for 298 of 305 participants who were 
randomized to the trial (560 samples, of which 262 had both baseline and 12 month 
samples) (Figure 1). The mean age of study participants was 72 years at randomisation, 
51% were male and 12% reported prior use of vitamin D supplements (400 IU of 
vitamin D3 daily) (Clarke et al., 2015). Compliance with instructions to take vitamin D 
supplements or placebo was high, with 90% (4000 IU), 92% (2000 IU) and 85% 
(placebo) reporting taking the capsules on all or most days at 12 months (Hin et al., 2016, 
Clarke et al., 2015). The overall mean plasma level of 25(OH)D was 50 nmol/L (standard 
error [SE] 1.04) at baseline and treatment was associated with mean plasma levels of 
25(OH)D of 136 (3.94), 106 (2.55) and 50 (1.68) among those allocated to 4000 IU, 2000 
IU, and placebo, after 12 months of treatment (unadjusted levels) (Table 1). 
 
We first performed principal components (PC) analysis to visualize the relationship 
between samples based on gene expression values. Considering all samples or paired 
samples within treatment or placebo groups, we found no visual evidence of clustering 
using up to the first 13 principal components (accounting for 41% of variance) (Figure 2, 
Supplementary Figure 2A and Supplementary Figures 3-6). The top 100 PCs accounted 
for 60% of the total variance (Supplementary Figure 3). 
 
We next formally tested the effects of vitamin D supplementation on genome-wide gene 
expression considering significantly differentially expressed probes at an FDR <5% for 
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any fold change in an unadjusted model. As expected after successful randomisation, we 
did not observe any significant differences in gene expression when comparing allocation 
groups at baseline (placebo baseline, 2000 IU baseline and 4000 IU baseline) 
(Supplementary Table 1). 
 
The pre-defined primary outcome sought to determine differences in gene expression in 
response to any dose of vitamin D compared with placebo. We compared differences in 
transcriptome among participants allocated to vitamin D (4000 IU or 2000 IU) at 0 vs 12 
months versus those allocated to placebo. Difference in difference analysis was estimated 
using (expression gene A following vitD12months - expression gene A vitDbaseline) - 
(expression gene A placebo12months - expression gene A placebobaseline). We found that 375 
probes (for 4000 IU minus placebo using the difference in difference estimate as above) 
and 329 probes (for 2000 IU minus placebo) were significantly differentially expressed 
following vitamin D supplementation (unadjusted p-value <0.05), but none remained 
significant after taking account of multiple comparisons (FDR <5%) (Supplementary 
Table 1). Use of quantile or variance stabilizing normalization (VSN) methods for data 
processing did not materially alter the results (Supplementary Figure 7, see Methods for 
details). The placebo group, with both baseline and 12 month sampling, is a stringent 
control that was used to account for the effect of time, placebo itself, technical artefacts 
or other sources of variation. After controlling for relevant confounders, there were no 
differences in gene expression between individuals allocated vitamin D versus those 
allocated placebo. It is possible that reliable detection of gene expression in response to 
vitamin D supplementation may require a larger sample size (Supplementary Figure 7).  
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Subsequent analyses considered less conservative comparisons as pre-specified (see data 
analysis protocol, Supplementary Appendix). We conducted two group comparisons of 
each arm (4000 IU at 12 months vs 4000 IU at baseline; and separately, 2000 IU at 12 
months vs 2000 IU at baseline), but did not find significant differences in gene 
expression (FDR <5%). We also compared 12-month samples (4000 IU at 12 months vs 
placebo at 12 months; 2000 IU at 12 months vs placebo at 12 months), but did not 
observe any significant differences (FDR <5%). Likewise, paired analysis for each of 
these comparisons did not yield significant differences (Supplementary Table 1).  
 
To maximize power, we combined all vitamin D allocated individuals before and after 
treatment (2000 IU plus 4000 IU vs their baseline samples, unpaired), but did not detect 
significant differences in expressed probes (FDR <5%). Paired sample comparisons (n = 
186, joint 2000 IU and 4000 IU) for this grouping indicated some significant differences 
following vitamin D supplementation (143 probes at <5% FDR; 292 probes at FDR 
<10%, fold change range 0.83–1.12, Supplementary Table 1). However, neither of these 
analyses took account of the differences in the placebo group and, hence, were less robust 
than the analyses of differences and random-effects detailed above. 
 
We hypothesized that differences in transcriptomes would be more evident when 
comparing individuals with low plasma levels of 25(OH)D. We compared those with pre-
treatment plasma levels of 25(OH)D <50 nmol/L versus those with 25(OH)D >50 
nmol/L, (124 vs 159, respectively, unadjusted model) regardless of the allocated 
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treatment, and separately cases of more extreme change (<25 nmol/L vs >75 nmol/L 
25(OH)D, 13 vs 30, respectively). Likewise, allocation to vitamin D had no significant 
differences in gene expression (FDR <5%, Supplementary Table 1). We repeated such 
comparisons using subsets with paired samples before and after treatment among 
individuals who at baseline were deficient (<50 nmol/L and separately for those with <25 
nmol/L), but did not detect any significant differences in either subgroup (FDR <5%, 
Supplementary Table 1). Finally, although we did not pre-specify it, we selected 
individuals whose change (delta) in 25(OH)D levels was high (vitD12months - vitDbaseline), 
regardless of allocated treatment. Although this analysis is more likely to be confounded 
it provided more power as more individuals with greater differences in plasma vitamin D 
in response to supplementation were included. We chose the median (+44.79 nmol/L) as 
this yielded the highest change in the maximum number of individuals (n=145). As 
expected, none of the placebo group had a difference of this magnitude (median: +2.58 
nmol/L). In paired analysis we found five genes significantly different at an FDR of <5% 
(Supplementary Table 1), but the effect sizes for these genes were small (fold change 
range: 0.81 – 1.12) and further work is needed to replicate such associations in other trial 
populations. Finally, given that gender specific effects have been noted previously 
(Pasing et al., 2017), we analyzed segregated samples (women only and men only) but 
did not find significant differences in paired analysis (women n = 144, men n = 141). 
 
Changes in plasma cytokine levels following vitamin D supplementation 
In addition, we assessed whether supplementation with vitamin D had any significant 
effect on plasma levels of cytokines (Table 1). Consistent with lack of effect on gene 
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expression results in the present and other previous studies (Ter Horst et al., 2016), we 
did not identify any significant effects of vitamin D supplementation on plasma levels on 
cytokines. Likewise, we found no significant correlations between plasma levels of 
25(OH)D and plasma levels of IFN-γ, IL-10, IL-8, IL-6 or TNF-α at 12 months 
(Supplementary Figures 8 and 9). Multivariate regression models testing the effect of 
supplementation after 12 months for either dose of vitamin D on changes in plasma 
cytokine levels (IFN-γ, IL-10, IL-8, IL-6 or TNF-α) after accounting for known 
confounders and baseline values did not show significant changes (Figure 3 and 
Supplementary Table 2).  
 
Individual responsiveness to vitamin D supplementation: impact of genotype 
This study lacked power to assess differences in the effects of treatment with vitamin D 
by differences in genome-wide genetic variation. We restricted our analysis to SNPs with 
prior evidence of association with plasma 25(OH) D levels from population GWAS 
(Wang et al., 2010) (rs12794714 [CYP2R1], rs2282679 [GC], rs7041 [GC] and 
rs7944926 [DHCR7/NADSYN1]) for which we had genotyping data available. Previous 
studies in twins suggested that summer levels of 25(OH)D were not strongly influenced 
by genetic variation (Orton et al., 2008, Karohl et al., 2010). Our pre-specified analysis 
assessed the hypothesis that genotype may modulate the response to vitamin D 
supplementation. We analyzed 25(OH)D levels following treatment with measurements 
at 6 and 12 months, using baseline vitamin D and other variables as covariates in a linear 
regression model (see Methods). We found that rs7041 (located on chromosome 4, GC) 
was significantly associated with response to vitamin D treatment with low dose vitamin 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
D (2000 IU) at 6 and 12 months (permuted p values 0.001 and 0.023 respectively) 
(Figure 4 and Supplementary Table 3). At high dose (4000IU), we found no significant 
effects of rs7041 (or other SNPs). Although higher doses may abrogate the genetic effect, 
larger studies with greater statistical power are needed to confirm or refute this 
hypothesis. 
 
We next considered whether there was evidence that genetic determinants of gene 
expression were modulated by supplementation with vitamin D by adopting a genetical 
genomics approach. Genetic variation is known to be an important determinant of 
individual gene expression and to be highly context-specific (Gibson et al., 2015). We 
hypothesized that genetic variation may be an important contributor to individual gene 
expression differences in response to vitamin D. Although our study did not detect 
differences in gene expression after supplementation, we carried out an expression 
quantitative trait analysis as pre-specified given that individual level effects on gene 
expression dependent on genotype may still occur. Following sample processing and 
quality control, we analyzed genotyping data on 497,136 variants for 288 individuals. We 
tested for evidence of association with gene expression using an addit ive linear model for 
14,972 probes, including the top principal components as covariates after maximizing for 
cis-eQTLs in each group (see Methods). We defined expression associated SNPs (eSNPs) 
as cis-eSNPs (those located within 1Mb of the gene expression probe) or trans-eSNPs 
(located >1Mb of the gene expression probe). At baseline, we found 31,568 cis-eQTLs 
(18,245 LD clumped index SNPs and 3,278 unique probes) and 34,254 (19,345 LD 
clumped index SNPs and 3,390 unique probes) at 12-months (unique SNP-probe pairs, 
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2000 IU and 4000 IU groups jointly to maximize sample size, FDR <5%) 
(Supplementary Table 4). There was a significant and positive overlap with comparable 
previously published data for whole blood eQTL (Westra et al., 2013) indicating high 
reproducibility despite large differences in sample size (1.75 fold-change overlap, q-value 
<0.001). To investigate response eQTLs present in samples from vitamin D 
supplemented individuals, we performed an analysis that took into account both effect 
size (gene expression differences) and statistical significance by obtaining eQTLs from 
the fold changes between treated (joint 2000 IU and 4000 IU 12 months’ 
supplementation) and their baseline values after correcting for principal components as 
outlined above. We found no significant associations involving response eQTLs (FDR 
<10%, Supplementary Table 4, Supplementary Figure 10). 
Discussion 
Overall, the present study demonstrated that allocation to high-dose oral vitamin D3 in 
305 older people had no significant effect on gene expression or plasma levels of 
cytokines when measured after 12 months despite achieving significantly higher plasma 
25(OH)D levels (Hin et al., 2016). To our knowledge, this is the largest randomized, 
placebo-controlled trial that assessed molecular changes and genetic effects following 
vitamin D supplementation.  
 
Previous studies lacking appropriate randomization or use of placebo controls may have 
been confounded by time. Both seasonal and age related effects on gene expression have 
been reported previously (Dopico et al., 2015, de Magalhaes et al., 2009). Careful design 
and analysis are required; data analysis protocols can be pre-specified with blinding 
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maintained. We demonstrated no significant effect of supplementation with either 2000 
IU or 4000 IU of vitamin D on genome-wide gene expression or on plasma levels of IFN-
γ, IL-10, IL-8, IL-6 and TNF-α after one year of supplementation. Although preliminary, 
the results of the present study suggest that plasma levels of vitamin D after 
supplementation can be modified by genetic variation.  
 
The findings of the present study agree with the main results of a recent trial assessing the 
effect of vitamin D supplementation on gene expression in subjects with reduced glucose 
tolerance (Pasing et al., 2017). Interestingly, this study observed differences in sub-group 
analyses by gender and circulating vitamin D quintiles. The trial had a smaller sample 
size, focused on a different population and lacked baseline controls however. 
 
The present study has several limitations. We did not collect samples within the first few 
hours or days following intervention and cannot exclude early transcriptomic changes. 
Indeed, other studies have observed changes in chromatin accessibility at candidate 
regions following vitamin D supplementation in peripheral blood mononuclear cells 
(Seuter et al., 2016). Similarly, other tissues and specific cell types may show differences 
not observable in whole blood samples. We cannot address whether inflammatory 
processes deplete plasma levels of vitamin D, but our results do not support the 
hypothesis that long-term supplementation modulates plasma levels of cytokines. The 
study population included Caucasian, community-dwelling older individuals. Younger 
individuals, those with particular diseases or different ethnicities may respond differently. 
Although we did not find differences for those with baseline vitamin D deficiency, our 
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study was not designed to target this group. Larger studies may find significant 
differences, albeit of likely smaller effect, and focused studies may identify changes in 
specific cell types or observe differences in individuals with 25(OH)D deficiency. 
 
This study demonstrated that genome-wide genetic variation, transcriptome and genetics 
of drug induced gene expression profiling can be integrated with biochemical and 
physiological measurements in the context of a randomized trial and may add important 
molecular and mechanistic insights. Interdisciplinary and collaborative efforts can guide 
the design and conduct of trials which require careful sample, data collection and 
analysis. 
 
Further studies are needed to replicate the null associations and to assess why there were 
no long-term detectable differences after vitamin D treatment on gene expression. 
Physiological mechanisms that regulate the metabolism of vitamin D may achieve a 
steady state. Higher plasma levels of 25(OH)D may allow resources to be mobilized 
when needed. Changes in chromatin may better reflect effects of vitamin D 
supplementation (Carlberg et al., 2018). Upregulation of catabolic enzymes, unobserved 
confounding, and tissue specificity, amongst others, may account for the null findings. 
The present study highlights the difficulty in translating results from model organisms, 
in-vitro and ex-vivo studies and argues for further integration of molecular and clinical 
studies from in vivo observations. 
 
Main figures and tables 
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Figure 1: CONSORT diagram for the functional genomics analysis of participants 
in the BEST-D study. eQTL: expression quantitative trait loci.  
Figure 2: Global gene expression by allocated treatment with either vitamin D or 
placebo supplementation was assessed using principal components analysis of 
variance. Principal components (PC) were calculated based on post-QC and VSN 
normalized gene expression signals. PC1 and PC2 (representing 15% and 8.5% of 
variance, respectively) are shown and colored according to time-point (final visit at 12 
months or at randomisation [baseline], panel A) and separately by treatment group 
(placebo, 2000 IU or 4000 IU, panel B). 
Figure 3: Boxplots of plasma cytokine levels and their corresponding transcripts 
before and after 12 months of vitamin D supplementation by allocated treatment.  
Gene expression (RNA) and circulating cytokine (protein) levels did not show changes 
after supplementation when accounting for baseline levels, known confounders and 
placebo (see Methods). VSN normalized mRNA levels (top row) and log-transformed 
protein levels (bottom row) of cytokines in whole-blood at baseline and 12 months (y-
axis) for each trial arm (x-axis: red (left) = placebo, green (middle) = 2000 IU, blue 
(right) = 4000 IU). 
Figure 4: Genetic association analysis following vitamin D supplementation.  
Boxplots of rs7041 (GC) showing post-supplementation plasma levels of 25(OH)D by 
allocated treatment. Associations with rs7041 are statistically significant at both 6 
(p=0.001, panel B) and 12 months (p=0.023, panel C) at 2000 IU using permutation to 
derive empirical p-values after adjusting for baseline 25(OH)D levels and other relevant 
variables (see Methods and Supplementary Table 3). x-axis: genotypes, red (left) = CC, 
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green (middle) = CA and blue (right) = AA. y-axis: 25(OH)D circulating levels (nmol/L) 
at baseline (A), 6 months (B) and 12 months (C). 
Table 1: Selected characteristics at baseline and at 12 months by allocated treatment 
with vitamin D or placebo. 
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Supporting Information 
Appendix 1: Data analysis protocol 
Appendix 2: Lay summary 
Supplementary Figure 1: Genotype data QC. 
Supplementary Figure 2: Gene expression QC. 
Supplementary Figures 3-6: Principal component analyses based on gene expression 
values. 
Supplementary Figure 7: Gene expression p-value distributions. 
Supplementary Figure 8: Heatmap of circulating cytokines and vitamin D. 
Supplementary Figure 9: Relationship between circulating cytokines and vitamin D 
supplementation. 
Supplementary Figure 10: Quantile-quantile plot of fold change eQTLs.  
Supplementary Table 1: Differential gene expression comparisons in vitamin D trial. (A) 
Legend and description of all comparisons. (B) Main comparisons. (C) All comparisons 
(including those considered main [ST1B]) 
Supplementary Table 2: Summary of analysis of covariance of circulating cytokines 
Supplementary Table 3: Genetic association results of candidate markers 
Supplementary Table 4: Expression quantitative trait locus analysis 
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Supplementary Table 6: Literature review of vitamin D clinical trials in the 12 months to 
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Figure 1: CONSORT diagram for the functional genomics analysis of participants 
in the BEST-D study. eQTL: expression quantitative trait loci. 
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Figure 2: Global gene expression by allocated treatment with either vitamin D or 
placebo supplementation was assessed using principal components analysis of 
variance. Principal components (PC) were calculated based on post-QC and VSN 
normalized gene expression signals. PC1 and PC2 (representing 15% and 8.5% of 
variance, respectively) are shown and colored according to time-point (final visit at 12 
months or at randomisation [baseline], panel A) and separately by treatment group 
(placebo, 2000 IU or 4000 IU, panel B). 
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Figure 3: Boxplots of plasma cytokine levels and their corresponding transcripts 
before and after 12 months of vitamin D supplementation by allocated treatment. 
Gene expression (RNA) and circulating cytokine (protein) levels did not show changes 
after supplementation when accounting for baseline levels, known confounders and 
placebo (see Methods). VSN normalized mRNA levels (top row) and log-transformed 
protein levels (bottom row) of cytokines in whole-blood at baseline and 12 months (y-
axis) for each trial arm (x-axis: red (left) = placebo, green (middle) = 2000 IU, blue (right) 
= 4000 IU). 
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Figure 4: Genetic association analysis following vitamin D supplementation. 
Boxplots of rs7041 (GC) showing post-supplementation plasma levels of 25(OH)D 
by allocated treatment. Associations with rs7041 are statistically significant at both 6 
(p=0.001, panel B) and 12 months (p=0.023, panel C) at 2000 IU using permutation to 
derive empirical p-values after adjusting for baseline 25(OH)D levels and other relevant 
variables (see Methods and Supplementary Table 2). x-axis: genotypes, red (left) = CC, 
green (middle) = CA and blue (right) = AA. y-axis: 25(OH)D circulating levels (nmol/L) at 
baseline (A), 6 months (B) and 12 months (C). 
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Table 1: Basic characteristics, baseline and 12 month values following vitamin D 
supplementation. 
 
Mean (SD) sem 
 CI95% lower, 
upper 
Change from 
baseline 
(mean, SD) p-value 
 
Pla
ceb
o 
200
0 
IU 
400
0 
IU 
Pl
ac
e
b
o 
2
0
0
0 
I
U 
4
0
0
0 
I
U 
Pla
ce
bo 
200
0 IU 
400
0 IU 
Pla
ce
bo 
20
00 
IU 
40
00 
IU 
Pl
ac
e
b
o 
2
0
0
0 
IU 
4
0
0
0 
IU 
Total 
n 
10
1 
102 102 - - - - - - - - - - - - 
Femal
e n 
49 51 50 - - - - - - - - - - - - 
Age 
71.
58 
(5.
64) 
71.
80 
(6.1
5) 
71.
30 
(5.5
2) 
0.
5
6 
0.
6
1 
0.
5
5 
66.
24, 
76.
92 
66.
46, 
77.
14 
65.
96, 
76.
64 
- - - - - - 
BMI 
28.
01 
(4.
65) 
27.
37 
(4.1
6) 
27.
22 
(4.7
2) 
0.
4
6 
0.
4
1 
0.
4
7 
22.
67, 
33.
35 
22.
03, 
32.
71 
21.
88, 
32.
56 
- - - - - - 
25(OH
)D 
baseli
ne 
47.
14 
(14
.62
) 
54.
85 
(22.
61) 
48.
75 
(15.
16) 
1.
4
5 
2.
2
5 
1.
5
0 
41.
80, 
52.
48 
49.
51, 
60.
19 
43.
41, 
54.
09 
- - - - - - 
25(OH
)D 12 
month
s 
50.
31 
(16
.34
) 
105
.80 
(25.
25) 
136
.25 
(38.
81) 
1.
6
8 
2.
5
5 
3.
9
4 
44.
97, 
55.
65 
100
.46, 
111
.14 
130
.91, 
141
.59 
3.5
0 
(7.
07
) 
50.
94 
(21
.93
) 
87.
07 
(35
.18
) 
5.
5
0E
-
0
6 
4.
6
9E
-
4
1 
6.
6
5E
-
4
3 
IFNg 
baseli
ne 
1.3
0 
(0.
70) 
1.5
0 
(0.9
4) 
1.4
2 
(0.7
8) 
0.
0
7 
0.
0
9 
0.
0
8 
-
4.0
4, 
6.6
4 
-
3.8
4, 
6.8
4 
-
3.9
2, 
6.7
6 
- - - - - - 
IFNg 
12 
month
s 
1.3
0 
(0.
73) 
1.5
3 
(0.8
4) 
1.4
2 
(0.8
1) 
0.
0
7 
0.
0
8 
0.
0
8 
-
4.0
4, 
6.6
4 
-
3.8
1, 
6.8
7 
-
3.9
2, 
6.7
6 
0.0
0 
(0.
74
) 
0.0
7 
(0.
94) 
0.0
2 
(0.
91) 
0.
9
7 
0.
4
8 
0.
7
9 
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IL10 
baseli
ne 
-
1.5
3 
(1.
12) 
-
1.4
0 
(1.1
0) 
-
1.5
8 
(0.9
8) 
0.
1
1 
0.
1
1 
0.
1
0 
-
6.8
7, 
3.8
1 
-
6.7
4, 
3.9
4 
-
6.9
2, 
3.7
6 
- - - - - - 
IL10 
12 
month
s 
-
1.4
0 
(0.
97) 
-
1.2
9 
(0.9
6) 
-
1.4
3 
(0.8
7) 
0.
1
0 
0.
1
0 
0.
0
9 
-
6.7
4, 
3.9
4 
-
6.6
3, 
4.0
5 
-
6.7
7, 
3.9
1 
0.1
2 
(0.
80
) 
0.1
6 
(0.
92) 
0.1
9 
(0.
87) 
0.
1
4 
0.
1
0 
0.
0
4 
IL6 
baseli
ne 
-
0.7
1 
(0.
67) 
-
0.6
0 
(0.7
3) 
-
0.7
0 
(0.7
9) 
0.
0
7 
0.
0
7 
0.
0
8 
-
6.0
5, 
4.6
3 
-
5.9
4, 
4.7
4 
-
6.0
4, 
4.6
4 
- - - - - - 
IL6 12 
month
s 
-
0.7
2 
(0.
67) 
-
0.5
8 
(0.7
5) 
-
0.6
1 
(0.6
6) 
0.
0
7 
0.
0
8 
0.
0
7 
-
6.0
6, 
4.6
2 
-
5.9
2, 
4.7
6 
-
5.9
5, 
4.7
3 
0.0
1 
(0.
76
) 
0.0
3 
(0.
64) 
0.1
2 
(0.
67) 
0.
9
4 
0.
5
9 
0.
0
7 
IL8 
baseli
ne 
1.2
2 
(0.
58) 
1.2
8 
(0.8
1) 
1.3
1 
(0.6
8) 
0.
0
6 
0.
0
8 
0.
0
7 
-
4.1
2, 
6.5
6 
-
4.0
6, 
6.6
2 
-
4.0
3, 
6.6
5 
- - - - - - 
IL8 12 
month
s 
1.1
4 
(0.
88) 
1.3
4 
(0.7
5) 
1.3
4 
(0.6
9) 
0.
0
9 
0.
0
8 
0.
0
7 
-
4.2
0, 
6.4
8 
-
4.0
0, 
6.6
8 
-
4.0
0, 
6.6
8 
-
0.0
7 
(0.
88
) 
0.0
6 
(0.
83) 
0.0
4 
(0.
57) 
0.
4
4 
0.
4
6 
0.
5
1 
TNFa 
baseli
ne 
0.5
8 
(0.
33) 
0.5
9 
(0.4
0) 
0.5
9 
(0.3
6) 
0.
0
3 
0.
0
4 
0.
0
4 
-
4.7
6, 
5.9
2 
-
4.7
5, 
5.9
3 
-
4.7
5, 
5.9
3 
- - - - - - 
TNFa 
12 
month
s 
0.5
7 
(0.
45) 
0.5
9 
(0.4
2) 
0.6
0 
(0.3
4) 
0.
0
5 
0.
0
4 
0.
0
3 
-
4.7
7, 
5.9
1 
-
4.7
5, 
5.9
3 
-
4.7
4, 
5.9
4 
-
0.0
2 
(0.
37
) 
0.0
2 
(0.
34) 
0.0
1 
(0.
27) 
0.
5
3 
0.
6
1 
0.
6
5 
IFNg 
baseli
7.0
4 
7.0
3 
7.0
3 
0.
0
0.
0
0.
0
1.7
0, 
1.6
9, 
1.6
9, 
- - - - - - 
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ne 
(mRN
A) 
(0.
20) 
(0.2
1) 
(0.1
8) 
2 2 2 12.
38 
12.
37 
12.
37 
IFNg 
12 
month
s 
(mRN
A) 
7.0
0 
(0.
15) 
7.0
3 
(0.2
3) 
7.0
2 
(0.2
2) 
0.
0
2 
0.
0
2 
0.
0
2 
1.6
6, 
12.
34 
1.6
9, 
12.
37 
1.6
8, 
12.
36 
-
0.0
5 
(0.
18
) 
-
0.0
1 
(0.
27) 
-
0.0
2 
(0.
22) 
0.
0
2 
0.
6
3 
0.
4
2 
IL10 
baseli
ne 
(mRN
A) 
6.8
7 
(0.
08) 
6.8
6 
(0.0
9) 
6.8
8 
(0.0
8) 
0.
0
1 
0.
0
1 
0.
0
1 
1.5
3, 
12.
21 
1.5
2, 
12.
2 
1.5
4, 
12.
22 
- - - - - - 
IL10 
12 
month
s 
(mRN
A) 
6.8
6 
(0.
08) 
6.8
7 
(0.0
7) 
6.8
7 
(0.0
8) 
0.
0
1 
0.
0
1 
0.
0
1 
1.5
2, 
12.
2 
1.5
3, 
12.
21 
1.5
3, 
12.
21 
-
0.0
1 
(0.
11
) 
0.0
1 
(0.
11) 
-
0.0
1 
(0.
12) 
0.
3
9 
0.
4
9 
0.
3
6 
IL6 
baseli
ne 
(mRN
A) 
6.9
3 
(0.
09) 
6.9
3 
(0.0
9) 
6.9
3 
(0.0
8) 
0.
0
1 
0.
0
1 
0.
0
1 
1.5
9, 
12.
27 
1.5
9, 
12.
27 
1.5
9, 
12.
27 
- - - - - - 
IL6 12 
month
s 
(mRN
A) 
6.9
3 
(0.
07) 
6.9
3 
(0.0
9) 
6.9
3 
(0.0
8) 
0.
0
1 
0.
0
1 
0.
0
1 
1.5
9, 
12.
27 
1.5
9, 
12.
27 
1.5
9, 
12.
27 
0.0
0 
(0.
11
) 
0.0
0 
(0.
12) 
0.0
0 
(0.
12) 
0.
8
2 
0.
8
2 
0.
9
4 
IL8 
baseli
ne 
(mRN
A) 
8.0
6 
(0.
61) 
8.1
0 
(0.6
1) 
7.9
9 
(0.6
6) 
0.
0
6 
0.
0
6 
0.
0
7 
2.7
2, 
13.
40 
2.7
6, 
13.
44 
2.6
5, 
13.
33 
- - - - - - 
IL8 12 
month
s 
(mRN
A) 
7.9
1 
(0.
61) 
7.9
3 
(0.6
5) 
7.9
0 
(0.6
7) 
0.
0
6 
0.
0
7 
0.
0
7 
2.5
7, 
13.
25 
2.5
9, 
13.
27 
2.5
6, 
13.
24 
-
0.1
3 
(0.
7) 
-
0.1
7 
(0.
73) 
-
0.0
8 
(0.
79) 
0.
0
9 
0.
0
4 
0.
3
4 
TNFa 
baseli
ne 
(mRN
8.3
0 
(0.
28) 
8.3
1 
(0.2
4) 
8.3
2 
(0.2
4) 
0.
0
3 
0.
0
3 
0.
0
2 
2.9
6, 
13.
64 
2.9
7, 
13.
65 
2.9
8, 
13.
66 
- - - - - - 
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A) 
TNFa 
12 
month
s 
(mRN
A) 
8.3
5 
(0.
24) 
8.3
4 
(0.2
4) 
8.3
6 
(0.2
4) 
0.
0
2 
0.
0
3 
0.
0
2 
3.0
1, 
13.
69 
3.0
0, 
13.
68 
3.0
2, 
13.
70 
0.0
5 
(0.
28
) 
0.0
3 
(0.
28) 
0.0
4 
(0.
27) 
0.
1
2 
0.
2
7 
0.
1
7 
                
Arithmetic mean, standard deviation (SD), standard error of the mean (sem), 95% 
confidence intervals (CI95%) and two-sided, univariate, paired t-test p-values 
shown (baseline versus 12 months within each arm).  
 
Values are for observed data only. Values 
presented are age in years, body mass index (BMI) 
in kg/m^2, 25(OH)D in nmol/L. 
       
Circulating cytokine values are natural 
logarithm transformed. mRNA values 
are VSN normalised. 
         
P-values are not adjusted for 
confounding, baseline values 
or multiple testing.  
           
Regression models and further results are shown in Supplementary 
Tables 1 (gene expression), 2 (genetic association), 3 (expression 
QTL) and 4 (circulating cytokines). 
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Study highlights 
 We carried out molecular analyses in a randomized, double-blind, placebo-
controlled, dose-finding clinical trial of daily vitamin D supplementation. 
 Participants were Caucasian, aged over 65 years with measurements collected 
at baseline and 12 months for placebo, 2000 IU or 4000 IU, respectively. 
 We did not find any significant differences in genomic, transcriptomic or 
selected cytokines in blood despite substantial changes in plasma 25(OH)D 
levels. 
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